Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

CLAG-M or FLAG-Ida Chemotherapy Followed Immediately by Related/Unrelated Reduced-Intensity Conditioning (RIC) Allogeneic Hematopoietic Cell Transplantation for Adults With Myeloid Malignancies at High Risk of Relapse: A Phase 1 Study

NCT04375631 is registered in ClinicalTrials.gov with Fred Hutchinson Cancer Center as lead sponsor.

NCT NCT04375631
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04375631 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
CLAG-M or FLAG-Ida Chemotherapy Followed Immediately by Related/Unrelated Reduced-Intensity Conditioning (RIC) Allogeneic Hematopoietic Cell Transplantation for Adults With Myeloid Malignancies at High Risk of Relapse: A Phase 1 Study
Lead sponsor
Fred Hutchinson Cancer Center
Phase
Phase 1
Overall status
Recruiting
Start date
December 3, 2020
Completion date
March 17, 2027
Enrollment
120 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent acute myeloid leukemia, recurrent chronic myelomonocytic leukemia, recurrent myelodysplastic syndrome, refractory acute leukemia of ambiguous lineage, refractory acute myeloid leukemia, refractory acute undifferentiated leukemia, refractory chronic myelomonocytic leukemia, refractory mixed phenotype acute leukemia, refractory myelodysplastic syndrome